Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Canntab Therapeutics Limited C.TFS

"Canntab Therapeutics Ltd is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. It has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use."


CSE:TFS - Post by User

Post by bpeterson Jan 17, 2018 5:54am
267 Views
Post# 27374546

See Jan 15th NR re share structure

See Jan 15th NR re share structureThe Jan 15th N.R. contained the following:
Canntab currently has 4,713,000 common shares outstanding. With the completion of its private placement Canntab has issued 1,251,914 Subscription Receipts for total gross proceeds of $5,007,656. Immediately prior to the completion of the Amalgamation, each Subscription Receipt will convert in to one Canntab share, resulting in there being 5,964,914 common shares of Canntab. Pursuant to the Amalgamation, shareholders of Canntab will receive 4 post-consolidation shares of Telferscot for each share of Canntab. Telferscot Shareholders are being asked to approve a consolidation of Telferscot Common Shares on a basis of 1 post-consolidation share for every 200 current, pre-consolidation shares (the Consolidation). Following the Consolidation, Telferscot will have approximately 574,284 shares and 50,750 options outstanding. Pursuant to the Amalgamation, Telferscot will issue 23,859,656 shares, 1,520,800 warrants and 1,880,000 options to the security holders of Canntab.
Hope this helps...


<< Previous
Bullboard Posts
Next >>